Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease
Open Access
- 4 November 1996
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 68 (3) , 285-290
- https://doi.org/10.1002/(sici)1097-0215(19961104)68:3<285::aid-ijc3>3.0.co;2-y
Abstract
Nasal T/NK‐cell lymphomas can be further separated into those of natural killer (NK) cell lineage or of T‐cell lineage, with differences in cellular phenotype, T‐cell receptor (TcR) gene rearrangement and TcR transcript expression. Both NK‐ and T‐cell subtypes are closely associated with Epstein‐Barr virus (EBV). In this study, EBV gene expression was determined in 23 cases of nasal lymphoma (NL) by in situ hybridisation (ISH), reverse transcriptase‐polymerase chain reaction (RT‐PCR) and immunohistochemistry (IH). Of the 23 cases, 19 were classified as NK‐cell and 4 as T‐cell tumours. ISH for EBV‐encoded small non‐polyadenylated RNAs showed that all cases, whether NK or T, harboured EBV in virtually all tumour cells. RT‐PCR demonstrated that NL of both subtypes expressed EBNAI of the QUK splice pattern, the latent membrane proteins, LMPI and 2 and the BamHI A rightward transcripts in the absence of EBNA2 mRNAs, compatible with the latency type II pattern. In addition, analysis of EBV protein expression by IH revealed a heterogeneous pattern of EBV gene expression at the single‐cell level consisting of both LMPI+ and LMPI‐ tumour cells, suggesting a mixture of latency I and II. Although 2 early lytic transcripts, BZLFI and BHRFI, were also detected in 13 and 10 cases, respectively, the lack of ZEBRA staining in any case indicates that these lytic transcripts are most likely expressed by rare cells in the biopsies entering lytic cycle. The viral transcriptional pattern similar to that of nasopharyngeal carcinoma and Hodgkin's disease suggests that EBV can exploit common regulatory mechanisms for gene transcription in diverse host cell types. Down‐regulation of immunogenic proteins (EBNA2‐EBNA6) in nasal lymphoma may enable tumour cells to evade host cytotoxic T‐cell surveillance. © 1996 Wiley‐Liss, Inc.Keywords
This publication has 30 references indexed in Scilit:
- Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell LymphomasThe American Journal of Surgical Pathology, 1996
- Detection of an epstein‐barr‐virus variant in T‐cell‐lymphoma tissues identical to the distinct strain observed in nasopharyngeal carcinoma in the taiwanese populationInternational Journal of Cancer, 1995
- Identification of a Novel Promoter Located Within theBamHI Q Region of the Epstein-Barr Virus Genome for the EBNA 1 GeneDNA and Cell Biology, 1995
- Evidence for lytic infection by Epstein‐Barr virus in mucosal lymphocytes instead of nasopharyngeal epithelial cells in normal individuals.Journal of Medical Virology, 1995
- Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologueEuropean Journal Of Cancer, 1994
- Epstein-Barr virus strategy in normal and neoplastic B cellsCell, 1994
- Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomasJournal of General Virology, 1994
- Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinomaJournal of General Virology, 1991
- PRESENCE OF EPSTEIN‐BARR VIRUS DNA IN NASAL LYMPHOMAS OF B AND ‘T’ CELL TYPEHematological Oncology, 1990
- An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cellsCell, 1985